Citing people familiar with the matter, Bloomberg reported that Johnson & Johnson agreed to pay more than $2.5 million to settle claims that the company’s Duragesic (fentanyl) caused the death of a plaintiff. The deal marks the first time the drugmaker has settled a case that went to trial over the transdermal pain patch.
As part of the accord, the company will no longer be required to pay $5.5 million in compensatory damages to the family of the plaintiff, awarded by a Florida jury in June, the report states. The jury in the case had concluded that the plaintiff's death in 2003 was caused by an overdose of fentanyl when his pain patch leaked, and that company officials were aware of the defects in the product but failed to adequately warn about its risks.
Johnson & Johnson declined to comment on the settlement news. Sales of Duragesic were about $1.3 billion last year.
To read more Top Story articles, click here.